Glenmark Pharmaceuticals Inc., USA launched a generic version of Travatan Z, a glaucoma treatment, called Travoprost ophthalmic solution (0.004%). This bioequivalent solution expands Glenmark's ophthalmic product line and addresses market demands. Travatan Z generated approximately $66.2 million in sales over the past year.
